imdevimab: Clinical Trials

3 completed, 2 terminated. 5 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 3, Terminated 2
Phase 2	2	Completed 1, Terminated 1

Follow imdevimab: new trials by email Literature Review of imdevimab trials Research Report on imdevimab

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers Casirivimab+Imdevimab - Healthy, Chronic Stable Illness	Phase 1	Completed	Regeneron Pharmaceuticals	45	2022-01-07	2025-10-14
COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 casirivimab+imdevimab - COVID-19	Phase 1	Terminated	Regeneron Pharmaceuticals	2	2021-12-16	2025-10-14
COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease REGN14256, imdevimab, casirivimab + imdevimab - SARS-CoV-2	Phase 1 / Phase 2	Terminated	Regeneron Pharmaceuticals	25	2021-11-08	2025-10-28
Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 REGN10933+REGN10987, Placebo - Healthy, Chronic Stable Illness	Phase 1	Completed	Regeneron Pharmaceuticals	974	2020-07-26	2022-01-26
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 REGN10933+REGN10987 combination therapy, Placebo - COVID-19	Phase 1 / Phase 2	Completed	Regeneron Pharmaceuticals	2252	2020-06-10	2023-01-27

Conditions studied

COVID-19 (5)  ·  Coronavirus Infections (3)  ·  Respiratory Distress Syndrome (1)

Sponsors

Regeneron Pharmaceuticals (5)

Countries

United States (5)  ·  Brazil (1)  ·  Chile (1)  ·  Mexico (1)  ·  Moldova (1)  ·  Romania (1)

Results publications

PMID 34473343, PMID 35713300, PMID 35895508, PMID 36255239, PMID 37229174